SPRO Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	170 518
Durchschnittsvolumen	323 929
Marktkapitalisierung	77.61M
EPS	$0 ( 2024-03-13 )
Nächstes Ertragsdatum	( $-0.0700 ) 2024-05-09
Last Dividend	$0.0150 ( 2015-09-16 )
Next Dividend	$0 ( N/A )
P/E	3.35
ATR14	$0.00700 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-01	Keutzer Timothy	Buy	239 731	Common Stock
2024-02-02	Keutzer Timothy	Sell	30 971	Common Stock
2024-02-02	Mahadevia Ankit	Sell	63 795	Common Stock
2024-02-01	Joseph Tamara L	Buy	239 731	Common Stock
2024-02-02	Joseph Tamara L	Sell	30 906	Common Stock

INSIDER POWER
59.24
Last 96 transactions
Buy: 6 234 250 \| Sell: 2 240 393

Volumen Korrelation

Lang: -0.33 (neutral)

Kurz: -0.39 (neutral)

Signal:(37.518) Neutral

Spero Therapeutics Inc Korrelation

10 Am meisten positiv korreliert
AKYA	0.855
COLB	0.855
CARE	0.85
ARQT	0.842
CBAN	0.835
FSEA	0.833
FBMS	0.832
FRBA	0.826
FBIZ	0.825
BIRD	0.823

10 Am meisten negativ korreliert
BNIXU	-0.902
OFLX	-0.802

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Spero Therapeutics Inc Korrelation - Währung/Rohstoff

-0.25
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

0.59
( weak )

Spero Therapeutics Inc Finanzdaten

Annual	2023
Umsatz:	$96.74M
Bruttogewinn:	$96.37M (99.62 %)
EPS:	$0.430

FY	2023
Umsatz:	$96.74M
Bruttogewinn:	$96.37M (99.62 %)
EPS:	$0.430

FY	2022
Umsatz:	$48.58M
Bruttogewinn:	$47.03M (96.82 %)
EPS:	$-1.280

FY	2021
Umsatz:	$18.26M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.91

Financial Reports:

No articles found.

Spero Therapeutics Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Spero Therapeutics Inc Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.56 - good (75.57%) | Divividend Growth Potential Score: 0.385 - No dividend growth expected in the near future

Information

First Dividend	$0.0100	2010-03-30
Last Dividend	$0.0150	2015-09-16
Next Dividend	$0	N/A
Payout Date	2015-10-07
Next Payout Date	N/A
# dividends	23	--
Total Paid Out	$0.285	--
Avg. Dividend % Per Year	0.00%	--
Score	2.92	--
Div. Sustainability Score	7.56
Div.Growth Potential Score	0.385
Div. Directional Score	3.97	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

2.92

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.240	1.500	5.19	7.79	[0 - 0.5]
returnOnAssetsTTM	0.130	1.200	5.66	6.79	[0 - 0.3]
returnOnEquityTTM	0.339	1.500	7.34	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.42	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.05	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0304	-1.500	9.49	-10.00	[0 - 0.6]
interestCoverageTTM	-20.59	1.000	-8.74	-8.74	[3 - 30]
operatingCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.415	[0 - 30]
freeCashFlowPerShareTTM	-0.623	2.00	-0.311	-0.623	[0 - 20]
debtEquityRatioTTM	0.0519	-1.500	9.79	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.811	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.200	1.000	8.00	8.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-5.95	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.542	0.800	9.72	7.78	[0.5 - 2]
Total Score				7.56

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.26	1.000	9.77	0	[1 - 100]
returnOnEquityTTM	0.339	2.50	8.29	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.623	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.623	2.00	-0.208	-0.415	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.00900	1.500	-3.39	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.334	1.000	-10.00	0	[0.1 - 0.5]
Total Score				0.385

Spero Therapeutics Inc

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.